Brand vs Compounded GLP-1: Cost, Safety & Legality

See if you qualify — 5-minute assessment →
Online questionnaire · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · cancel anytime

At a glance: brand vs compounded GLP-1

	Brand-name GLP-1	Compounded GLP-1
FDA-approved?	Yes	No
Studied in pivotal trials	Yes (STEP, SURMOUNT, SELECT)	No
Typical monthly cost	~$299–$499 self-pay (list ~$1,000–$1,350)	~$99–$399 (via telehealth)
Made by	Novo Nordisk / Eli Lilly	State-licensed compounding pharmacy (503A or 503B)
Regulatory oversight	FDA-approved + manufacturer cGMP	State board of pharmacy (503A)
Access route	Insurance or direct self-pay programs	Prescription, patient-specific, via licensed clinician
When appropriate	Standard first-line option; insured or self-pay	Genuinely patient-specific need, clinician-guided

Prices as of June 2026; change frequently. Clinical trial data applies to FDA-approved branded medications only — not to any compounded product.

Cost: the gap is real, but smaller than it was

When compounded GLP-1s first gained widespread attention, the cost comparison was stark: brand list prices of $1,000–$1,350/month versus compounded alternatives at a fraction of that. That gap has narrowed materially since 2025.

Novo Nordisk and Eli Lilly both launched direct self-pay programs in response to compounding competition. NovoCare (Novo's direct program) offers Wegovy® at approximately $349/month for uninsured or out-of-pocket patients; LillyDirect lists Zepbound® at $299–$449/month depending on dose. These programs have eligibility requirements and paperwork — some patients navigate them smoothly, others do not — but they represent a meaningful narrowing of the historical gap.

On the compounded side, as of June 2026, telehealth programs typically price compounded semaglutide and tirzepatide in the $99–$399/month range depending on dose, program structure, and what is included (medication only versus medication plus clinical support). Prices on both sides of this comparison move often; any specific figure is potentially out of date within a quarter.

The honest cost question is not "brand list versus compounded" — it is "brand self-pay versus compounded," and for patients with insurance that covers Wegovy® or Zepbound®, neither self-pay option may be the right comparison at all.

For a detailed, current breakdown, see our GLP-1 cost guide for 2026, the dedicated compounded vs. brand GLP-1 cost comparison, and our publicly available live pricing dataset at huggingface.co/datasets/nouriadmin/glp1-telehealth-pricing-2026.

What "FDA-approved" actually means — and why it matters

FDA approval is not just a label. For Wegovy® (semaglutide 2.4 mg) and Zepbound® (tirzepatide), approval required years of large-scale clinical trials, independent FDA review of safety and efficacy data, and ongoing manufacturing audits. What that process produces for patients:

• Documented efficacy: the drug's effect in a defined patient population is on file with the FDA and reflected in the prescribing label. When a clinician prescribes Wegovy®, there is a public record of what it did in a 68-week randomized controlled trial of 1,961 people.
• Post-market safety monitoring: the FDA tracks adverse events, can require label updates, and can compel a recall. The boxed warning on GLP-1s about thyroid C-cell tumors exists because this monitoring process works.
• Manufacturing standards: FDA-approved products are produced under Current Good Manufacturing Practice (cGMP) regulations — verified potency, purity, and sterility at scale.
• Dosing certainty: the dose stated on the label has been validated. A 2.4 mg injection contains 2.4 mg of active semaglutide.

Compounded GLP-1s carry none of these FDA-verified guarantees. A state-licensed 503A pharmacy operates under state board of pharmacy oversight — which is real regulatory oversight — but the FDA has not reviewed, verified, or approved the compounded product. The NIDDK notes that FDA-approved prescription medications for weight management have demonstrated safety and efficacy through the clinical trial and approval process; compounded versions fall outside that review.

What compounding actually is: 503A and 503B pharmacies

Compounding is a long-established pharmacy practice that predates FDA drug approval as a modern framework. Understanding the two regulatory categories helps you evaluate any provider claiming to offer compounded GLP-1.

503A pharmacies compound medications for individual patient prescriptions. They operate under state board of pharmacy oversight, not direct FDA manufacturing oversight. A 503A pharmacy must have a valid, patient-specific prescription before it compounds. This is the category most telehealth programs use for compounded GLP-1 prescriptions.

503B outsourcing facilities are registered with the FDA and may produce larger batches without individual patient prescriptions, but they face significantly stricter requirements including FDA facility inspection and cGMP compliance. They are, in effect, manufacturers operating in a compounding-adjacent framework.

Neither type of facility produces an FDA-approved drug when it compounds a molecule. Compounded drugs are explicitly excluded from FDA drug approval by statute. That is not a regulatory technicality — it means the FDA has not verified the compounded product's safety, efficacy, or quality for the indication being treated. This is why the statement "compounded semaglutide is not FDA-approved and is not therapeutically equivalent to Wegovy®" is accurate and legally required language, not a mere disclaimer.

For how these distinctions apply specifically to semaglutide, see our compounded semaglutide vs. Wegovy® comparison.

The legal landscape in 2026: what changed and what remains

The legal footing for compounded GLP-1s shifted significantly in 2025 and continues to evolve.

The shortage era (2022–2024). During the semaglutide and tirzepatide shortage period, the FDA's drug shortage exemption allowed broader compounding of these drugs, effectively creating a large market of compounded GLP-1 products. Many providers operated at scale that exceeded the traditional patient-specific model.

2025: shortages declared resolved. The FDA declared the semaglutide shortage resolved in early 2025 and the tirzepatide shortage resolved in mid-2025. With the shortage exemption gone, the legal basis for broadly supplying compounded GLP-1s to the general market narrowed significantly. The FDA issued guidance that compounding should now genuinely be patient-specific — for example, a documented clinical reason why the standard FDA-approved product is not appropriate — rather than a routine, lower-cost substitute.

2026: proposed further restriction. The FDA proposed adding semaglutide and tirzepatide to its list of drug products that may not be compounded by 503B outsourcing facilities, with a public comment period closing in late June 2026. If finalized, this would restrict bulk outsourcing-facility compounding of these molecules further. It does not eliminate 503A patient-specific compounding.

What remains legal as of mid-2026: a state-licensed 503A pharmacy compounding for a specific, identified patient, with a valid prescription from a licensed prescriber, for a documented patient-specific reason. This is the narrow, legitimate use case that has existed throughout the debate. It is clinician-guided, not self-serve.

For FDA guidance directly: FDA: Human Drug Compounding and FDA: Postmarket Drug Safety Information for Patients and Providers. For tirzepatide-specific considerations, see our compounded tirzepatide vs. Zepbound® comparison.

Safety: it depends on who makes it

The FDA's public warnings about compounded GLP-1s have consistently targeted specific failure modes — not compounding as a category. Understanding the real risk factors helps you separate legitimate programs from dangerous ones.

Documented risks the FDA has flagged:

• Unregulated online sellers with no verifiable pharmacy, no prescription requirement, and no clinical oversight
• Products using non-standard "salt forms" of semaglutide (semaglutide sodium or semaglutide acetate) — these are not the same molecule as the active ingredient in Wegovy® or Ozempic®, and the FDA has stated they are not appropriate for compounding
• Dosing errors — compounded GLP-1 is typically supplied as a multi-dose vial requiring self-injection; incorrect dosing instructions or unlabeled concentrations are a documented harm pathway
• Counterfeit products and illegally imported active pharmaceutical ingredients with no chain-of-custody verification

What legitimate compounding looks like: a named, state-licensed 503A pharmacy with a verifiable physical address; a valid prescription issued by a licensed physician or advanced practitioner who has reviewed your health history; use of the correct active ingredient (semaglutide base, not a salt form); and clear dosing and administration guidance. Any legitimate telehealth provider names its pharmacy. If a provider won't tell you which pharmacy compiles your medication or won't give you a verifiable pharmacy name, that is a red flag.

The FDA consumer alert on unapproved GLP-1 products is worth reading before choosing any provider.

What the published research shows — about the branded molecules

The clinical trials that established GLP-1s as a class studied the FDA-approved branded products under controlled conditions. This research belongs to those branded drugs and cannot be attributed to any compounded version. The data below describes the FDA-approved molecules, not Nouri's compounded product or any other compounded GLP-1.

Semaglutide (the molecule in Wegovy® and Ozempic®): In the STEP 1 trial (Wilding et al., NEJM 2021), adults with obesity receiving once-weekly semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, versus 2.4% with placebo. In the SELECT trial (Lincoff et al., NEJM 2023), semaglutide reduced major adverse cardiovascular events by approximately 20% in adults with overweight or obesity and established cardiovascular disease — a finding that went beyond weight management.

Tirzepatide (the molecule in Zepbound® and Mounjaro®): In the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity receiving tirzepatide 15 mg achieved a mean body weight reduction of approximately 20.9% at 72 weeks, versus 3.1% with placebo.

Head-to-head: The SURMOUNT-5 trial (NEJM 2025) directly compared tirzepatide 10–15 mg versus semaglutide 2.4 mg in adults with obesity. At 72 weeks, tirzepatide produced approximately 20.2% mean weight reduction versus 13.7% with semaglutide. These are outcomes for the FDA-approved branded drugs in that specific head-to-head trial — not a description of what any compounded product will achieve.

These figures represent population averages from controlled trials; individual outcomes with any GLP-1 treatment vary substantially based on adherence, dose, lifestyle, co-morbidities, and individual biology. For a detailed comparison of the two molecules, see our tirzepatide vs. semaglutide guide.

How to evaluate a compounded GLP-1 program

If you and a licensed clinician determine compounded GLP-1 is clinically appropriate for you, here is what to look for when evaluating a program:

• Named, verifiable pharmacy: the provider should name its 503A pharmacy and provide enough information for you to confirm state licensing. Pharmacy boards in most states have online license verification.
• Real clinical intake: a licensed physician, NP, or PA should review your health history — not auto-issue a prescription after a checkbox survey. Not everyone who applies should qualify, and a legitimate program enforces that.
• Correct active ingredient: ask whether the product uses semaglutide base (not a salt form). For tirzepatide, the same principle applies.
• Dose escalation and monitoring: GLP-1s are started at a low dose and escalated gradually to manage side effects. A responsible program has a structured escalation protocol and clinical check-ins at each stage.
• What is included: a prescription and a vial shipped to your door is not a program. Weight management on GLP-1s is more effective with nutrition guidance, behavioral support, and ongoing clinical access. Understand what you are actually getting before comparing costs.
• Transparent all-in pricing: confirm whether the quoted price includes medication at all dose levels, or whether the price escalates with dose.

For cost context across the market, see our semaglutide cost breakdown and tirzepatide cost breakdown.

Related comparisons

• Compounded Semaglutide vs Wegovy®
• Compounded Tirzepatide vs Zepbound®
• Tirzepatide vs Semaglutide: which is right for you?
• Compounded vs brand GLP-1: full cost comparison

Where Nouri fits

If you and a licensed clinician determine a GLP-1 is appropriate, Nouri offers compounded semaglutide and tirzepatide as part of The Program — one all-inclusive membership that combines the compounded medication (when prescribed) with a personalized nutrition plan, a movement plan, and ongoing clinician support, at one price that does not change with dose.

Pricing as of June 2026:

Therapy	6-month plan	3-month plan	Monthly
Compounded semaglutide	$120/mo ($720 every 6 months)	$145/mo ($435 every 3 months)	$175/mo
Compounded tirzepatide	$175/mo ($1,050 every 6 months)	$199/mo ($597 every 3 months)	$225/mo

Medication is prepared by Jungle Jim's Pharmacy (a state-licensed 503A pharmacy in Fairfield, OH) and VialsRX. Nouri is LegitScript-certified. Free, discreet home delivery in all 50 states. Not all applicants qualify — a U.S.-licensed clinician reviews your health intake before any prescription is issued.

The Nouri Promise: if you are not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Compounded semaglutide and tirzepatide contain the same active ingredient as the brand-name medications named in this article, but they are not FDA-approved and are not the same as, or therapeutically equivalent to, those products.

Compounded GLP-1 costs may be eligible for FSA or HSA reimbursement as a qualified medical expense under IRC §213(d) — this is reimbursement-only, subject to your plan's terms and, in some cases, a letter of medical necessity. Confirm eligibility with your plan administrator.

Start your 5-minute assessment →
Online questionnaire · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · cancel anytime

Frequently asked questions

Is compounded GLP-1 just as good as the brand?

Compounded GLP-1s are not FDA-approved and were not studied in the clinical trials, so no one can claim they are "just as good" or therapeutically equivalent. They contain the same active ingredient, but they are a different, non-FDA-verified product. Talk to a clinician about what is appropriate for you.

Why is compounded GLP-1 less expensive than the brand?

Compounded GLP-1s do not carry the research, regulatory approval, and brand-marketing costs of an FDA-approved product, and they are prepared by compounding pharmacies rather than large pharmaceutical manufacturers. As of June 2026, compounded versions run roughly $99–$399/month versus brand self-pay programs at $299–$499/month — though prices change frequently and the gap has narrowed since manufacturers launched direct-pay options.

Is compounded GLP-1 still legal in 2026?

Compounding from a state-licensed 503A pharmacy with a valid prescription remains legal. However, the broad shortage-based allowance ended when the FDA resolved the semaglutide and tirzepatide shortages in 2025. Compounding is now meant to be patient-specific. Compounded GLP-1s are not FDA-approved. Confirm current rules with a licensed clinician or pharmacy.

Are compounded GLP-1s being banned or going away?

Mass-produced compounded GLP-1s have been sharply restricted since the FDA declared the shortages resolved in 2025, and in 2026 the FDA proposed restricting bulk compounding further. They are not outright banned — genuinely patient-specific compounding from a licensed 503A pharmacy remains available — but the broad, routine version is going away. Confirm the current rules with a clinician before enrolling with any provider.

Can compounded GLP-1 costs be reimbursed through an FSA or HSA?

Compounded GLP-1 prescribed by a licensed physician may be eligible for FSA or HSA reimbursement under IRC §213(d) as a qualified medical expense. This is reimbursement-only — there is no direct FSA/HSA card acceptance at point of sale. Some plans may require a letter of medical necessity. Eligibility varies; confirm with your plan administrator before assuming coverage.

What is a 503A pharmacy and why does it matter?

A 503A pharmacy compounds medications for individual patient prescriptions under state board of pharmacy oversight. It is distinct from a 503B outsourcing facility, which faces stricter FDA manufacturing requirements and can compound batches without individual prescriptions. For compounded GLP-1, a named, state-licensed 503A pharmacy with a verifiable address is one of the primary signals separating legitimate compounding from unregulated sellers — and it is what regulators and clinicians look for when evaluating whether a program operates within the law.

Sources & references

1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss
2. FDA: Human Drug Compounding
3. NIDDK: Prescription Medications to Treat Overweight & Obesity
4. Wilding et al. — STEP 1 (semaglutide 2.4 mg), NEJM 2021
5. Jastreboff et al. — SURMOUNT-1 (tirzepatide), NEJM 2022
6. SURMOUNT-5 head-to-head (tirzepatide vs. semaglutide), NEJM 2025
7. Lincoff et al. — SELECT (semaglutide cardiovascular outcomes), NEJM 2023
8. FTC: Health Products Compliance Guidance

By Nouri Editorial Team. Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

This article is general education, not medical advice — talk to a licensed clinician about what is right for you. Ozempic®, Wegovy®, and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Clinical-trial results described in this article are from the FDA-approved branded medications; compounded semaglutide and tirzepatide have not been studied in these trials, are not FDA-approved, and are not the same as — or therapeutically equivalent to — the brand-name drugs. GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors and are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); other serious risks include pancreatitis and gallbladder disease; these medications are not for use during pregnancy. Prices are as of June 2026 and change frequently; verify current pricing at joinnouri.com/becoming. FSA/HSA reimbursement eligibility varies by plan; confirm with your plan administrator. The Nouri Promise (30-day full refund) is available on 3-month and 6-month plans only; see joinnouri.com for current terms.